Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines

International Journal of Oncology

Volumn 12, Issue 1, 1998, Pages 161-170

  Nigam, Ankesh ^a   Yacavone, Robert F ^a   Zahurak, Marianna L ^a   Johns, Christina M S ^a   Pardoll, Drew M ^a   Piantadosi, Steven ^a   Levitsky, Hyam I ^a   Nelson, William G ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cancer immunotherapy; Cancer vaccines; Cyclophosphamide; Doxorubicin; Granulocyte macrophage colony stimulating factor

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOLOGICAL ADJUVANT; MESSENGER RNA;

ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; COLON CARCINOMA; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; ANIMAL; BAGG ALBINO MOUSE; CD8+ T LYMPHOCYTE; CELL CULTURE; COLON TUMOR; CYTOTOXIC T LYMPHOCYTE; EXPERIMENTAL NEOPLASM; HUMAN; IMMUNOLOGY; MALE; MULTIMODALITY CANCER THERAPY; SECRETION; SURVIVAL RATE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; RNA, MESSENGER; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0031975265     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.1.161     Document Type: Article

References (72)

1. Pardoll DM: Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 13: 399-415, 1995.
2. Dranoff G and Mulligan RC: Gene transfer as cancer therapy. Adv Immunol 58: 417-454, 1995.
3. Houghton AN: On course for a cancer vaccine. Lancet 345: 1384-1385, 1995.
4. Gilboa E, Lyerly HK, Vieweg J and Saito S: Immunotherapy of cancer using cytokine gene-modified tumor vaccines. Semin Cancer Biol 5: 409-417, 1994.
5. Watanabe Y, Kuribashi K, Miyatake S, Nishihara K, Nakagama E, Taniyama T and Skata T: Exogenous expression of murine interferon gamma eDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA 86: 9456-9460, 1989.
6. Tepper RI, Pattengale PK and Leder P: Murine interleukin-4 displays potent antitumor activity in vivo. Cell 57:503-512, 1989.
7. Li WQ, Diamantstein T and BIankenstein T: Lack of tumorigenicity of interleukin 4 autocrine growing cells seems related to the antitumor function of interleukin 4. Mol Immunol 27: 1331-1337, 1990.
8. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B and Frost P: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397-403, 1990.
9. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R and Gilboa E: Interleukin-2 gene transfer into tumor ceils abrogates tumorgenicity and induces protective immunity. J Exp Med 4: 1217-1224, 1990.
10. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R and Gilboa E: Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long-lasting antitumor immunity. Cancer Res 50: 7820-7825, 1990.
11. Asher AL, Mule J J, Kasid A, Restofo NP, Salo JC, Reihert CM, Jaffe G, Fendly B, Kriegler M and Rosenberg SA: Murine tumor cells transduced with the gene for tumor necrosis factor-it. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol 146: 3227-3234, 1991.
12. Blankenstein T, Qin Z, Uberia K, Muller W, Rosen H, Volk H-D and Diamantstein T: Tumor suppression after tumor cell-targeted tumor necrosis factor factor alpha gene transfer. J Exp Med 173: 1047-1052, 1991.
13. Colombo MP, Ferrari G, Stoppacciaro A, Parenza M, Rodolfo M, Mavilio F and Parmiani G: Granulocyte colony-stimulating factor gene transfer suppresses tumorigenesis of a murine adenocarcinoma bt vivo. J Exp Med 173: 889-897, 1991.
14. Hock H, Dorsch M, Diamantstein T and BIankenstein T: Interleukin 7 induces T-cell-dependent tumor rejection. J Exp Med 174: 1291-1298, 1991.
15. Golumbek P, Lazenby A, Levitsky HI, Jaffee E, Karasuyama H, Baker M and Pardoll DM: Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254: 713-716, 1992.
16. Porgador A, Tzehoval E, Katz A, Vadai E, Revel M, Feldman M and Eisenbach L: Interieukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 52: 3679-3686, 1992
17. Aoki T, Tashiro K, Miyatake S, Kinashi T, Nakano T, Oda Y, Kikuchi H and Honjo T: Expression of routine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc Natl Acad Sci USA 89: 3850-3854, 1992.
18. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky HI, Brose K, Jackson, V, Hamada H, Pardoll DM and Mulligan R: Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific, and long lasting antitumor immunity. Proc Natl Acad Sci USA 90: 3539-3543, 1993.
19. Porgador A, Tzehoval E, Vadai E, Feldman M and Eisenbach L: Immunotherapy via gene therapy: comparison of the effects of tumor cells transduced with interleukin-2, interleukin-6, or interferon-gamma genes. J Immunother 14: 191-201, 1993.
20. Porgador A, Gansbacher B, Bannerji R, Tzehoval E, Gilboa E, Feldman M and Eisenbach L: Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells. Int J Cancer 53: 471-477, 1993.
21. Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Cohen LK, Dranoff G, Pardoll DM, Mulligan RC and Simons JW: Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 151: 622-628, 1994.
22. Vieweg J, Rosenthal FM, Bannerji R, Hestin WD, Fair WR, Gansbacher B and Gilboa E: Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 54: 1760-1765, 1994.
23. Saito S, Banncrji R, Gansbacher B, Rosenthal FM, Romanenko P, Heston WD, Fair WR and Gilboa E: Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res 54: 3516-3520, 1994.
24. Bannerji R, Arroyo CD, Cardon-Cardo C and Gilboa E: The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J Immunol 152: 2324-2332, 1994.
25. Carducci MA, Ayyagari SR, Sanda MG and Simons JW: Gene therapy for human prostate cancer. Translational research in the hormone refractory Dunning prostate cancer model. Cancer 75: 2013-2020, 1995.
26. Jaffee EM, Thomas MC, Huang AY-C, Hauda KM, Levitsky HI and Pardoll DM: Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J Immunother 1-9: 1-8, 1996.
27. Komada Y, Zhang SL, Zhou YW, Hamada M, Shibata T, Azuma E and Saturai M: Cellular immunosuppression in children with acute lymphoblastic leukemia: effect of consolidation chemotherapy. Cancer Immunol Immunother 35: 271-276, 1992.
28. Orsini F, Eppolito C, Ehrke MJ and Mihich E: Inhibition by selected anticancer agents of the development of primary cellmediated immunity against allogeneic tumor cells in culture. Cancer Treatment Rep 64:211-218, 1980.
29. Browne MJ, Hubbard SM, Longo DL, Fisher R, Wesley R, Ihde DC, Young RC and Pizzo PA: Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy. Ann Intern Med 104: 338-344, 1986.
30. Brunvand MW, Collins C, Livingston RB and Raghu G: Pnet,nocystis carinii pneumonia associated with profound lymphopenia and abnormal T-lymphocyte subset ratios during treatment for early-stage breast carcinoma. Cancer 67: 2407-2409, 1991.
31. Bartlett MS and Smith JW: Pneumocystis carinii, an'opportunist in immunocompromised patients. Clin Microbiol Rev 4: 137-149, 1991.
32. Ehrke M J, Mihich E, Berd D and Mastrangelo M J: Effects of anticancer drags on the immune system in humans. Semin Oncol 16: 230-253, 1989.
33. Ehrke M J, Ho RLX and Mihich E: Modifications of antitumor immune effects by Adriamycin. In: New Horizons of Tumor Immunotherapy. Torisu M and Yoshida T (eds). Elsevier Science Publishers, BV, pp467-479, 1989.
34. Maccubbin DL, Wing KR, Mace KF, Ho RL, Ehrke MJ and Mihich E: Adriamycin-induced modulation of host defenses in tumor-bearing mice. Cancer Res 52: 3572-3576, 1992.
35. Corbett TH, Griswold DP Jr, Roberts BI, Peckham JC and Schable FM Jr: Tumor induction relationships in the development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 35: 2434-2439, 1975.
36. Griswold DP and Corbett TH: A colon tumor model for anticancer agent development. Cancer 36: 2441-2444, 1975.
37. Gough NM, Metcalf D, Gough J, Grail D and Dunn RA: Structure and expression of the mRNA for murine granulocyte-macrophage colony stimulating factor. EMBO J 4: 645-653, 1985.
38. Danos O and Mulligan RC: Safe and efficient generation of recombinant retrovirus with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA 85: 6460-6464, 1988.
39. Wilson JM, Jefferson DM, Chowdhury JR, Novikoff PM, Johnston DE and Mulligan RC: Retrovirus-mediated transduction of adult hepatocyes. Proc Natl Acad Sci USA 85: 3014-3018, 1988.
40. Sarmiento M, Glasebrook A and Fitch F: IgG and lgM antibodies reactive with different determinants on the molecular complex bearing Lyt-2 antigen block T cell-mediated cytolysis in the absence of complement. J Immunol 125: 2665-2672, 1980.
41. Berns AJM, Clift S, Cohen LK, Donehower RC, Dranoff G, Hauda KM, Jaffce EM, Lazenby A J, Marshall FF, Mulligan RC, Nelson WG, Owens AH, Pardoll DM, Parry G, Partin AH, Piantidosi S, Simons JW and Zabora JR: Clinical protocol: phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum Gene Ther 6: 347-368, 1995.
42. Simons JW, Jaffee E, Weber CA, Levitsky HI, Nelson WG, Carducci MA, Lazenby A J, Cohen LK, Finn CC, Clift SM, Hauda KM, Beck LA, Leiferman KM, Owens AH Jr, Piantidosi S, Dranoff G, Mulligan RC, Pardoll DM and Marshall FF: Bioactivity of autologous in'radiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 57: 1537-1546, 1997.
43. Maguire HC Jr and Ettore VL: Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig. J Invest Dermatol 48: 39-42, 1967.
44. Askenase PW, Hayden BJ and Gershon RK: Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses. J Exp Med 141: 697-702, 1975.
45. GIaser M: Regulation of specific cell-mediated cytotoxic response against SV40-induced tumor associated antigens by deletion of suppressor T cells with cyclophosphamide in mice. J Exp Med 149: 774-779, 1979.
46. GIaser M: Augmentation of specific immune responses against syngeneic SV40-induced sarcoma in mice by depletion of suppressor T cells with cyclophosphamide. Cell Immunol 48: 339-345, 1979.
47. Yoshida S, Nomoto K, Himeno K and Takeya K: Immune response to syngeneic or autologous testicular cells in mice. I. Augmented delayed footpad reaction in cyclophosphamidetreated mice. Clin Exp Immunol 38:211-217, 1979.
48. Goto M, Misuoka A, Sugiyama M and Kitano M: Enhancement of delayed hypersensitivity reaction with varieties of anti-cancer drugs. A common biological phenomenon. J Exp Med 154: 204-209, 1981.
49. Turk JL and Parker D: Effect of cyclophosphamide on immunological control mechanisms. Immunol Rev 65:99-113, 1982.
50. Berd D, Mastrangelo MJ, Engstrom PF, Paul A and Maguire H: Augmentation of the human immune response by cyclophosphamide. Cancer Res 42: 4862-4866, 1982.
51. Berd D, Maguire HC Jr and Mastrangelo M J: Induction of cellmediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46: 2572-2577, 1986.
52. Scwartz HS and Grindey GB: Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression. Cancer Res 33: 1837-1844, 1973.
53. Mantovani A, Vecchi A, Tagliabue A and Spreafico F: The effects of adriamycin and daunomycin on antitumoral immune effector mechanimsm in an allogeneic system. Eur J Cancer 12: 371-379, 1976.
54. Ehrke M J, Ryoyma K, Tomazic V, Cohen SA and Mihich E: Selective imbalances of cellular immune responses by adriamycin. Rec Results Cancer Res 75: 195-199, 1980.
55. Santoni A, Riccardi C, Sorci V and Herberman RB: Effects of adriamycin on the activity of mouse natural killer cells. J Immunol 124: 2329-2335, 1980.
56. Cohen SA, Ehrke M J, Ryoyma K and Mihich E: Augmentation of the phagocytic activity of murine spleen cell populations induced by adriamycin. Immunopharmacology 5: 75-84, 1982.
57. Hisano G and Fidler I J: Systemic activation of macrophages by liposome-entrapped muramyl tripeptide in mice pretreated with the chemotherapeutic agent adriamycin. Cancer Immunol Immunother 14: 61-66, 1982.
58. Cohen,SA, Salazar D and Wicher J: Adriamycin-induced activation of NK activity may initially involve LAF production. Cancer lmmunol Immunother 15: 188-193, 1983.
59. Ehrke M.J, Tomazic V, Ryoyma K, Cohen SA and Mihich E: Adriamycin induced immunomodulation: dependence upon time of administration. Int J Immunopharmac 5: 43-48, 1983.
60. Ehrke M J, Ryoyma K and Cohen SA: Cellular basis for adriamycin-induced augmentation for ceil-mediated cytotoxicity in culture. Cancer Res 44: 2497-2504, 1984.
61. Salazar D and Cohen SA: Multiple tumoricidal effector mechanisms induced by adriamycin. Cancer Res 44: 2561-2566, 1984.
62. Arinaga S, Akiyoshi T and Tsuji H: Augmentation of the cellmediated cytotoxic response induced in mixed cell culture by adriamycin. Jpn J Cancer Res 76: 414-419, 1985.
63. Ehrke M J, Maccubbin D, Ryoyma K, Cohen SA and Mihich E: Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in mice. Cancer Res 46: 54-60, 1986.
64. Arinaga S, Akiyoshi T and Tsuji H: Augmentation of the generation of cell-mediated cytotoxicity after a single dose of adriamycin in cancer patients. Cancer Res 46: 4213-4216, 1986.
65. Mace K, Mayhew E, Mihich E and Ehrke M J: Alterations in murine host defense functions by adriamycin or liposomeencapsulated adriamycin. Cancer Res 48: 130-136, 1988.
66. Maccubbin DL, Cohen SA and Ehrke M J: Indomethacin modulation of adriamycin-induced effects on multiple cytolytic cffcctor functions. Cancer Immunol Immunother 31: 373-380, 1990.
67. Zaleskis G, Ho RL, Diegelman P, Maccubbin D, Ujhazy P, Mihich E and Ehrke M J: Intracellular doxorubicin kinetics in lymphoma cells and !ymphocytes infiltrating the tumor area in vivo. Oncol Res 6: 183-194, 1994.
68. Huang AYC, Gulden PH, Woods AS, Thomas MC, Tong CD, Wang W, Englehard VH, Pasternack G, Cotter R, Hunt D, Pardoll DM and Jaffe EM: The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci USA 93: 9730-9735, 1996.
69. Metlay JP, Purel E and Steinman RM: Control of the immune response at the level of antigen-presenting cells: a comparison of the function of dendritic cells and B lymphocytes. Adv Immuno147:45-115, 1989.
70. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM and Schuler G: Proliferating dendritic cell progenitors in human blood. J Exp Med 180: 83-93, 1994.
71. Huang A, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, and Levitsky H: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264: 961-965, 1994.
72. Cox DR: Regression models and life tables (with discussion). J Roy Statist Soc Set B Metb 34: 187-220, 1972.